Literature DB >> 20872811

The impact of preoperative chemoradiotherapy on advanced low rectal cancer.

Ping-Sheng Kao1, Shih-Ching Chang, Ling-Wei Wang, Rheun-Chuan Lee, Wen-Yi Liang, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Jen-Kou Lin.   

Abstract

BACKGROUND: Preoperative chemoradiotherapy (CCRT) followed by radical resection is an option for advanced low rectal cancer. This study was aimed to clarify the impact of CCRT on patients' outcome. PATIENTS AND METHODS: One hundred thirty-six patients with rectal cancer (<10  cm from anal verge) were enrolled prospectively between July 2000 and December 2004. The preoperative clinical stage was T3, T4, or node-positive disease. Sixty-nine and 67 patients underwent surgery with and without preoperative CCRT, respectively. The regimen of pre-op CCRT was a radiation dosage of 45  Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin.
RESULTS: There was no statistical difference in the preserved anorectal function between two groups after 5 years of follow-up (62.3% vs. 47.8%; P = 0.125). The 5-year overall survival and disease-free survival (DFS) percentage were 88.4% and 76.8% for patients with preoperative CCRT, and 65.7% and 58.2% for patients without CCRT, respectively. Patients with preoperative CCRT had a higher overall survival rate and DFS (P = 0.001 and 0.015).
CONCLUSIONS: In patients with advanced low rectal cancer, preoperative CCRT followed by radical surgery significantly improved overall survival and DFS compared with surgery alone. The effect of sphincter preservation with preoperative CCRT is questionable.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872811     DOI: 10.1002/jso.21711

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

2.  Tailored selection of the interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer: analysis based on the pathologic stage or chemoradiation response.

Authors:  Kai-yun You; Rong Huang; Lu-ning Zhang; Pei-rong Ding; Wei-wei Xiao; Bo Qiu; Hui Chang; Zhi-fan Zeng; Zhi-zhong Pan; Yuan-hong Gao
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-09       Impact factor: 4.553

3.  Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.

Authors:  Deniz Tural; Fatih Selcukbiricik; Özcan Yıldız; Olgun Elcin; Sibel Erdamar; Sabri Güney; Fuat Demireli; Evin Büyükünal; Süheyla Serdengeçti
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

4.  Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors.

Authors:  Moonkyoo Kong; Seong Eon Hong; Woo Suk Choi; Si-Young Kim; Jinhyun Choi
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

5.  Oncologic Impact of Fewer Than 12 Lymph Nodes in Patients Who Underwent Neoadjuvant Chemoradiation Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer.

Authors:  Woo Ram Kim; Yoon Dae Han; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

6.  Local recurrence after curative resection for rectal carcinoma: The role of surgical resection.

Authors:  Jung-A Yun; Jung Wook Huh; Hee Cheol Kim; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Woo Yong Lee; Ho-Kyung Chun
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.

Authors:  Kai-Lin Yang; Shung-Haur Yang; Wen-Yih Liang; Ying-Ju Kuo; Jen-Kou Lin; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Huann-Sheng Wang; Shih-Ching Chang; Lee-Shing Chu; Ling-Wei Wang
Journal:  Radiat Oncol       Date:  2013-03-01       Impact factor: 3.481

8.  Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0.

Authors:  Kai-yun You; Rong Huang; Pei-rong Ding; Bo Qiu; Guan-qun Zhou; Hui Chang; Wei-wei Xiao; Zhi-fan Zeng; Zhi-zhong Pan; Yuan-hong Gao
Journal:  Int J Colorectal Dis       Date:  2014-01-29       Impact factor: 2.571

9.  Radiotherapy for stage IIA rectal cancer may not benefit all.

Authors:  Xiang Hu; Ya-Qi Li; Qing-Guo Li; Yan-Lei Ma; Jun-Jie Peng; San-Jun Cai
Journal:  Oncotarget       Date:  2017-07-29

10.  The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Guo-Chen Liu; Xu Zhang; E Xie; Xin An; Pei-Qiang Cai; Ying Zhu; Jing-Hua Tang; Ling-Heng Kong; Jun-Zhong Lin; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.